BioSpace News Archive

ENB Therapeutics, Inc., a clinical stage biotechnology company pioneering a new and differentiated class of therapeutics targeting the endothelin B receptor (ETBR) inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, ENB-003.

Embleema Inc. and CDISC have announced a collaboration to develop new standards for experimental assays and bioinformatics protocols to facilitate monitoring the activity of Cell and Gene Therapy Products (CGTP).

FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm.

Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).

Acutis, a specialized clinical and biosciences company, announced Dr. Abdel Halim has joined as Chief Scientific Officer and Executive Vice President.

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has issued a management information circular in respect of the annual general meeting of shareholders to be held on June 23, 2022 (the “Circular”).

Texas Spine Care Center announced today their 10th patient enrolled in the Centinel Spine, LLC, Multicenter, Prospective, Randomized Controlled Trial Comparing the Safety and Effectiveness of prodisc® C SK and prodisc® C Vivo to Mobi-C® Cervical Disc in the Treatment of Two-Level Symptomatic Cervical Disc Disease (SCDD).

Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostic technology, today announced the addition of two senior executives, each of whom will play a pivotal role in guiding the company toward its goal of delivering the first FDA-cleared non-invasive glucose monitor.

GelSight, a pioneer in tactile intelligence technology, announced the release of GelSight Mobile™ 2.4.

According to Vision Research Reports, the e-clinical solutions market size is expected to hit around US$ 22.7 billion by 2030 and is projected to grow at a registered CAGR of 13.7% during forecast period 2021 to 2030.